Further uncertainty for biotech/agritech patent applicants
Are products exclusively obtained by essentially biological processes patentable at the EPO?
Read more
Are products exclusively obtained by essentially biological processes patentable at the EPO?
Read more
Richard Bray and Samuel Bird discuss the patentability of mobile apps.
Read more
Eli Lilly v Genentech: the question of SPCs based on third party MAs is referred to the CJEU.
Read more
Likely to affect the patentability of ‘simulation’ methods, Howard Read explores the issues behind a European Patent Office (EPO) referral to the Enlarged Board of Appeal (EBA).
Read more
After years of controversy, the Technical Board of Appeal (TBA) of the EPO has recently decided that products obtained by essentially biological processes can be patent protected (T1063/18).
Read more
What’s the problem with ‘functional limitations’?
Read more